Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

1.

[Th17-mediated relapsing-remitting multiple sclerosis is nonresponsive to interferon-β1b].

Zhang X, Zhang Q, Shi X, Yin R, Zhang Z, Hou X.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2013 Jul;29(7):751-3. Chinese.

PMID:
23837989
[PubMed - indexed for MEDLINE]
2.

Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.

Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.

Clin Ther. 2008 Jun;30(6):1102-12. doi: 10.1016/j.clinthera.2008.06.013.

PMID:
18640466
[PubMed - indexed for MEDLINE]
3.

Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.

Río J, Rovira A, Tintoré M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X.

Mult Scler. 2008 May;14(4):479-84. doi: 10.1177/1352458507085555.

PMID:
18562504
[PubMed - indexed for MEDLINE]
4.

A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta.

Paolillo A, Pozzilli C, Giugni E, Tomassini V, Gasperini C, Fiorelli M, Mainero C, Horsfield M, Galgani S, Bastianello S, Buttinelli C.

Eur J Neurol. 2002 Nov;9(6):645-55.

PMID:
12453081
[PubMed - indexed for MEDLINE]
5.

Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.

Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M.

Mult Scler. 2010 Jul;16(7):848-54. doi: 10.1177/1352458510369147. Epub 2010 May 20.

PMID:
20488825
[PubMed - indexed for MEDLINE]
6.

The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up.

Reggio E, Nicoletti A, Fiorilla T, Politi G, Reggio A, Patti F.

J Neurol. 2005 Oct;252(10):1255-61. Epub 2005 Jun 6.

PMID:
15940386
[PubMed - indexed for MEDLINE]
7.

Comparing efficacy and side effects of a weekly intramuscular biogeneric/biosimilar interferon beta-1a with Avonex in relapsing remitting multiple sclerosis: a double blind randomized clinical trial.

Nafissi S, Azimi A, Amini-Harandi A, Salami S, shahkarami MA, Heshmat R.

Clin Neurol Neurosurg. 2012 Sep;114(7):986-9. doi: 10.1016/j.clineuro.2012.02.039. Epub 2012 Mar 18.

PMID:
22429566
[PubMed - indexed for MEDLINE]
8.
9.

Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-beta.

Annunziata P, Giorgio A, De Santi L, Zipoli V, Portaccio E, Amato MP, Clerici R, Scarpini E, Moscato G, Iudice A, Vacca G, Orefice G, Morra VB, Maimone D.

J Neurol Sci. 2006 May 15;244(1-2):97-102. Epub 2006 Feb 13.

PMID:
16473370
[PubMed - indexed for MEDLINE]
10.

Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.

Saida T, Tashiro K, Itoyama Y, Sato T, Ohashi Y, Zhao Z; Interferon Beta-1b Multiple Sclerosis Study Group of Japan.

Neurology. 2005 Feb 22;64(4):621-30.

PMID:
15728282
[PubMed - indexed for MEDLINE]
11.

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.

Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass AD, Wynn DR, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA.

Lancet Neurol. 2011 Apr;10(4):338-48. doi: 10.1016/S1474-4422(11)70020-5.

PMID:
21397567
[PubMed - indexed for MEDLINE]
12.

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.

O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T; BEYOND Study Group, O'Connor P, Filippi M, Arnason B, Cook S, Goodin D, Hartung HP, Kappos L, Jeffery D, Comi G.

Lancet Neurol. 2009 Oct;8(10):889-97. doi: 10.1016/S1474-4422(09)70226-1. Epub 2009 Sep 2. Erratum in: Lancet Neurol. 2011 Feb;10(2):115. Lancet Neurol. 2009 Nov;8(11):981. Lancet Neurol. 2012 Jan;11(1):27. Cree, B [added]; Harung, H-P [corrected to Hartung, H-P].

PMID:
19729344
[PubMed - indexed for MEDLINE]
13.

The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. The Danish Multiple Sclerosis Group.

Koch-Henriksen N, Sørensen PS.

Mult Scler. 2000 Jun;6(3):172-5.

PMID:
10871828
[PubMed - indexed for MEDLINE]
14.

Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients.

Frank JA, Richert N, Bash C, Stone L, Calabresi PA, Lewis B, Stone R, Howard T, McFarland HF.

Neurology. 2004 Mar 9;62(5):719-25.

PMID:
15007120
[PubMed - indexed for MEDLINE]
15.

CD45RA+ ICAM-3+ lymphocytes in interferon-beta1b-treated and -untreated patients with relapsing-remitting multiple sclerosis.

Chatzimanolis N, Kraus J, Bauer R, Engelhardt B, Bregenzer T, Kuehne BS, Tofighi J, Laske C, Stolz E, Blaes F, Voigt K, Traupe H, Kaps M, Oschmann P.

Acta Neurol Scand. 2004 Dec;110(6):377-85.

PMID:
15527450
[PubMed - indexed for MEDLINE]
16.

Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment.

Lus G, Romano F, Scuotto A, Accardo C, Cotrufo R.

Eur Neurol. 2004;51(1):15-20. Epub 2003 Nov 18.

PMID:
14631124
[PubMed - indexed for MEDLINE]
17.

Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.

Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, Spitaleri D, Lus G, Vacca G, Carotenuto B, Salvatore E, Brunetti A, Tedeschi G, Brescia Morra V.

Mult Scler. 2010 Apr;16(4):450-4. doi: 10.1177/1352458509358909. Epub 2010 Feb 11.

PMID:
20150398
[PubMed - indexed for MEDLINE]
18.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
[PubMed - indexed for MEDLINE]
19.

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.

Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag B; REGARD study group.

Lancet Neurol. 2008 Oct;7(10):903-14. doi: 10.1016/S1474-4422(08)70200-X. Epub 2008 Sep 11.

PMID:
18789766
[PubMed - indexed for MEDLINE]
20.

MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.

Gasperini C, Paolillo A, Giugni E, Galgani S, Bagnato F, Mainero C, Onesti E, Bastianello S, Pozzilli C.

Mult Scler. 2002 Apr;8(2):119-23.

PMID:
11990868
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk